Premarket Decliner
TIL Instil Bio12.29+1.02+9.1%
Premarket:6.63-5.66 (-46.1%)
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
Globe NewswireTue, 6-Jan 7:00 AM
TIL Instil Bio24.61+8.39+51.7%
Premarket:19.92-4.69 (-19.1%)
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
Globe NewswireFri, 23-May 7:00 AM
